[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA202090389A1 - ANTI-CTLA-4 ANTIBODIES AND THEIR APPLICATION - Google Patents

ANTI-CTLA-4 ANTIBODIES AND THEIR APPLICATION

Info

Publication number
EA202090389A1
EA202090389A1 EA202090389A EA202090389A EA202090389A1 EA 202090389 A1 EA202090389 A1 EA 202090389A1 EA 202090389 A EA202090389 A EA 202090389A EA 202090389 A EA202090389 A EA 202090389A EA 202090389 A1 EA202090389 A1 EA 202090389A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
ctla
application
cytotoxic
protein
Prior art date
Application number
EA202090389A
Other languages
Russian (ru)
Inventor
Айнур Херманн
Элла Иоффе
Елена Бурова
Гэвин ТЕРСТОН
Уилльям Олсон
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Priority claimed from PCT/US2018/043936 external-priority patent/WO2019023482A1/en
Publication of EA202090389A1 publication Critical patent/EA202090389A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Данное изобретение относится к антителам, которые связываются с белком 4, ассоциированным с цитотоксическими Т-лимфоцитами (CTLA-4 - cytotoxic T-lymphocyte-associated protein 4), и к способам их применения. В различных вариантах осуществления данного изобретения указанные антитела являются полностью человеческими антителами, которые специфично связываются с CTLA-4. В некоторых вариантах осуществления указанные антитела по данному изобретению пригодны для ингибирования или нейтрализации активности CTLA-4, что обеспечивает средства для активации Т-клеток и/или для лечения заболевания или расстройства, такого как рак или вирусная инфекция.This invention relates to antibodies that bind to protein 4 associated with cytotoxic T-lymphocytes (CTLA-4 - cytotoxic T-lymphocyte-associated protein 4), and to methods for their use. In various embodiments of the invention, these antibodies are fully human antibodies that specifically bind to CTLA-4. In some embodiments, the antibodies of the invention are suitable for inhibiting or neutralizing CTLA-4 activity, which provides means for activating T cells and / or for treating a disease or disorder such as cancer or viral infection.

EA202090389A 2018-06-15 2018-07-26 ANTI-CTLA-4 ANTIBODIES AND THEIR APPLICATION EA202090389A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862685599P 2018-06-15 2018-06-15
PCT/US2018/043936 WO2019023482A1 (en) 2017-07-27 2018-07-26 Anti-ctla-4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA202090389A1 true EA202090389A1 (en) 2020-06-24

Family

ID=71138800

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090389A EA202090389A1 (en) 2018-06-15 2018-07-26 ANTI-CTLA-4 ANTIBODIES AND THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA202090389A1 (en)

Similar Documents

Publication Publication Date Title
PH12020500078A1 (en) Anti-ctla-4 antibodies and uses thereof
PH12018500664A1 (en) Anti-lag3 antibodies and uses thereof
MX2021009852A (en) Human antibodies to pd-1.
CY1124771T1 (en) ANTI-SORTILINE ANTIBODIES AND METHODS OF USING THEM
PH12016501384A1 (en) Human antibodies to pd-l1
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
PE20191759A1 (en) OPTIMIZATION OF ANTIBODIES THAT BIND TO THE LYMPHOCYTE ACTIVATION GENE 3 (LAG-3) AND USES OF THEM
MY196006A (en) Anti-C5 Antibodies and Uses Thereof
EA201991214A1 (en) ANTIBODIES AGAINST PD-1 AND THEIR COMPOSITION
WO2020136145A3 (en) Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies
EA202091590A1 (en) ANTIBODIES AGAINST PD-L1 AND THEIR APPLICATION OPTIONS
BR112019024654A2 (en) binding protein nkg2d, cd16 and ror1 or ror2
EA202090204A1 (en) ANTI-CD137 ANTIBODIES
EA201890297A1 (en) ANTIBODY TO CD154, possessing improved characteristics of binding, function and safety, and its use in human immunotherapy
BR112022003956A2 (en) anti-cd73 antibodies
EA202090372A1 (en) UNIVERSAL AVT CONNECTIONS AND THEIR APPLICATION
AR112770A1 (en) ANTI-CTLA-4 ANTIBODIES AND THEIR USES
EA202090389A1 (en) ANTI-CTLA-4 ANTIBODIES AND THEIR APPLICATION
EA202092265A1 (en) ANTIBODIES AGAINST CD137 FOR COMBINATION WITH ANTIBODIES AGAINST PD-L1
EA202092151A1 (en) ANTIBODIES
EA202091738A1 (en) METHODS FOR TREATMENT OF CANCER WITH ANTIBODIES-ANTAGONISTS TO PD-1
EA201890762A1 (en) ANTIBODIES TO LAG3 AND THEIR APPLICATIONS
EA202092279A1 (en) ANTIBODIES TO MICA AND / OR MICB AND THEIR APPLICATION
EA201992324A1 (en) ANTI-TREM2 ANTIBODIES AND WAYS OF THEIR APPLICATION
EA201892748A1 (en) ANTIBODIES TO PD-L1 AND OPTIONS FOR THEIR APPLICATION